Point-of-care (POC) diagnostics startup Chronus Health Inc. reeled in $22 million in a series A round led by Tarsadia Investments. The company plans to use the funds to scale its research, engineering and data science teams and hasten product and technology development. Monta Vista Capital, Sosv and Savantus Ventures also participated in the financings, along with an unidentified strategic investor.
Canadian company Future Fertility Inc. is hatching plans to expand the user base for its flagship egg prediction software product, Violet, for egg cryopreservation. The noninvasive image analysis tool uses artificial intelligence (AI) to evaluate the reproductive potential of mature eggs. Investors are backing the Toronto-based company with $6 million in series A funds, so it can expand internationally and develop additional assessment products.
LONDON – Natural killer (NK) cell therapy specialist Onk Therapeutics Ltd. has raised $21.5 million in a series A, enabling it to move three lead programs into proof-of-concept animal testing and to progress manufacturing and scale-up of its cord blood-derived cells.
PARIS – Milvue SAS completed a series A round, raising more than $9 million towards deployment of its artificial intelligence-based software solution used for diagnosis and full triage of osteoarticular pathologies in emergency departments.
Depixus Ltd. has raised $35.4 million in an oversubscribed series A financing to push commercialization of its Magna multiomics system. The series A round was co-led by Lansdowne Partners and PSIM Fund, with participation from Casdin Capital and existing investor Arix Bioscience. The funds bring the company's total equity and grant funding to more than $47 million.
Xandar Kardian Inc. closed a $10 million series A funding round to support the rollout of the company’s contactless health monitoring solution. Phoenix Venture Partners led the round with participation from Portfolia Active Aging & Longevity Fund, Taronga Ventures and others. “With the new financing round, Xandar Kardian looks forward to expanding its core team in Toronto and in the United States, in addition to placing increased emphasis on R&D and mass production for its technologies,” Xandar Kardian co-founder and CEO Sam Yang told BioWorld.
Endogena Therapeutics Inc., of San Francisco, has raised another $20 million in a series A funding round to progress a regenerative medicine that could use stem cells to “heal” the damage caused by eye disease retinitis pigmentosa (RP).
Sonic Incytes Medical Corp. collected $7.3 million in a series A fundraising round to bring its liver-focused point-of-care ultrasound solution to commercialization. Nimbus Synergies led the round with participation from Nicola Wealth, Mint Venture Partners, Consortium Medteq, Wavemaker Three-Sixty Health, Gaingels, INP Capital and several angel investors. The round was oversubscribed by 150%. The hand-held Velacur system noninvasively quantifies liver volume, stiffness and attenuation, critical factors in diagnosing and monitoring liver disease in a process that takes about five minutes and can be performed in a physician’s office. The system received FDA clearance late last year.
Protein profiling startup Nomic Bio has secured $17 million in an oversubscribed series A financing led by Lux Capital. The funds will be used to expand the company’s servicing and manufacturing labs in Montreal and Boston, to broaden access to its proteomic platform by scaling profiling capacity to 100,000 samples per quarter starting in the second quarter of 2022 and by scaling its protein-detection method, called nELISA, to 500 on-boarded proteins.
LONDON – Europe’s latest antibody-drug conjugate (ADC) specialist, Emergence Therapeutics AG, will be going head to head with pioneer Seagen Inc.’s approved ADC, Padcev, after raising €87 million (US$97.9 million) in a series A round.